IMPORTANT MEDICAL DISCLAIMER: This information is intended for educational purposes only and does not constitute medical advice. It is designed to be a comprehensive clinical reference for healthcare professionals, but it should not be used as a substitute for professional medical judgment. Patient care decisions must always be made by a qualified healthcare provider after a thorough evaluation of the individual patient's condition, medical history, and current clinical guidelines. Dosages, indications, and contraindications may change, and clinicians are responsible for verifying all information with current, authoritative sources and exercising their independent clinical judgment.

---

Aspirin

Overview

• Definition: Aspirin (acetylsalicylic acid, ASA) is a non-steroidal anti-inflammatory drug (NSAID) and an antiplatelet agent. It is a salicylate derivative that exerts its therapeutic effects primarily by irreversibly inhibiting cyclooxygenase (COX) enzymes, particularly COX-1. This inhibition leads to reduced production of prostaglandins and thromboxane A2 (TXA2).
• Epidemiology: Aspirin is one of the most widely used medications globally. Its use for cardiovascular disease prevention is extensive, especially in populations with established atherosclerotic cardiovascular disease (ASCVD) or those at high risk. However, its role in primary prevention has evolved over time due to a clearer understanding of bleeding risks. The prevalence of aspirin use varies by country and population, but it remains a cornerstone in the management of acute coronary syndromes and stroke.
• Classification:
  • Chemical Class: Salicylate, Acetylated Salicylic Acid.
  • Pharmacological Class: Antiplatelet agent, Non-steroidal anti-inflammatory drug (NSAID), Analgesic, Antipyretic.
  • Therapeutic Class: Antiplatelet, Antithrombotic, Analgesic, Anti-inflammatory, Antipyretic.

Pathophysiology

• Mechanism:
  1. Irreversible COX-1 Inhibition: Aspirin acetylates a serine residue (Ser-529) in the active site of cyclooxygenase-1 (COX-1) irreversibly, leading to its inactivation. In platelets, COX-1 is the primary enzyme responsible for synthesizing thromboxane A2 (TXA2) from arachidonic acid. TXA2 is a potent vasoconstrictor and platelet aggregator. Since platelets are anucleated and cannot synthesize new COX-1, the antiplatelet effect of aspirin lasts for the lifetime of the platelet (7-10 days).
  2. COX-2 Inhibition: Aspirin also inhibits cyclooxygenase-2 (COX-2), the enzyme primarily involved in prostaglandin synthesis at sites of inflammation, pain, and fever. This mechanism accounts for its analgesic, anti-inflammatory, and antipyretic effects. However, higher doses are typically required for significant COX-2 inhibition.
  3. Low Dose vs. High Dose: At low doses (e.g., 75-100 mg/day), aspirin selectively inhibits platelet COX-1, maximizing its antiplatelet effect while minimizing inhibition of endothelial COX-2 (which produces prostacyclin, an anti-aggregatory and vasodilatory prostaglandin). At higher doses, its anti-inflammatory and analgesic effects become more prominent due to increased COX-2 inhibition, but this also increases the risk of side effects, including gastrointestinal (GI) and renal complications.
• Risk Factors (for indications of use):
  • Established atherosclerotic cardiovascular disease (ASCVD): Prior myocardial infarction (MI), stroke, transient ischemic attack (TIA), peripheral artery disease (PAD), stable angina.
  • High calculated ASCVD risk (e.g., >20% 10-year risk).
  • Certain cardiac procedures (e.g., percutaneous coronary intervention with stenting).
  • Atrial fibrillation (though typically anticoagulants are preferred for stroke prevention).
  • Venous thromboembolism prevention in specific high-risk settings (e.g., post-orthopedic surgery if anticoagulants are contraindicated).
  • Preeclampsia risk in high-risk pregnant individuals.
• Protective Factors (for aspirin's effects or safe use):
  • Use of proton pump inhibitors (PPIs) or H2 blockers to mitigate GI bleeding risk.
  • Enteric-coated formulations (though evidence for reduced GI bleed risk compared to uncoated is mixed).
  • Careful patient selection based on risk-benefit assessment.
  • Concomitant use with other antiplatelet agents (e.g., P2Y12 inhibitors) in specific settings (e.g., dual antiplatelet therapy post-ACS/PCI) to enhance anti-thrombotic protection.

Clinical Presentation (Indications and Adverse Effects)

Signs and Symptoms (related to use or adverse effects)

• Cardinal Features (Indications):
  • Acute Coronary Syndromes (ACS): Chest pain, dyspnea, diaphoresis.
  • Ischemic Stroke/TIA: Unilateral weakness, aphasia, visual disturbances.
  • Preeclampsia Prophylaxis: Asymptomatic (preventive use).
• Cardinal Features (Adverse Effects):
  • GI Irritation/Bleeding: Epigastric pain, nausea, vomiting, melena, hematemesis, hematochezia.
  • Bleeding: Petechiae, ecchymoses, epistaxis, gingival bleeding.
  • Aspirin-Exacerbated Respiratory Disease (AERD): Nasal congestion, rhinorrhea, bronchospasm (asthma-like symptoms) triggered by aspirin.
  • Salicylism (Mild Toxicity): Tinnitus, vertigo, hearing impairment, nausea, vomiting.
  • Reye's Syndrome (Children): Persistent vomiting, lethargy, irritability, confusion (often following a viral illness).
• Early Signs (Adverse Effects):
  • Mild epigastric discomfort, indigestion.
  • Easy bruising.
  • Tinnitus (initial sign of salicylism).
• Advanced Signs (Adverse Effects):
  • Overt GI bleeding (melena, hematemesis).
  • Anemia symptoms (fatigue, pallor, dyspnea on exertion).
  • Hemorrhagic stroke (headache, neurological deficits).
  • Severe metabolic acidosis, hyperpyrexia, coma, seizures in acute aspirin toxicity.
• Atypical Presentations:
  • Occult GI bleeding: Chronic blood loss leading to iron deficiency anemia without overt symptoms.
  • Silent ulceration: Gastric or duodenal ulcers without significant pain.
  • Idiosyncratic reactions: Beyond typical allergic or GI effects.

Physical Examination (related to adverse effects)

• Inspection:
  • Pallor: Suggestive of anemia from chronic or acute blood loss.
  • Jaundice: Possible sign of severe hepatic dysfunction (rare, but can occur in toxicity).
  • Petechiae/Ecchymoses: Evidence of increased bleeding tendency.
  • Respiratory distress/Wheezing: Suggestive of AERD or severe aspirin toxicity.
• Palpation:
  • Abdominal tenderness: Epigastric tenderness in gastropathy/ulceration.
• Special Tests:
  • Stool guaiac test (FOBT): To detect occult GI bleeding.
  • Neurological exam: To assess for signs of stroke (ischemic or hemorrhagic).

Diagnostic Approach (for indications, contraindications, and adverse effects)

History Taking

• Key Questions:
  • Indications: History of MI, stroke, TIA, angina, PAD, cardiovascular risk factors (hypertension, hyperlipidemia, diabetes, smoking, family history).
  • Contraindications/Risks:
    • History of GI bleeding, peptic ulcer disease, esophageal varices.
    • Bleeding disorders (hemophilia, von Willebrand disease, thrombocytopenia).
    • Recent surgery or planned surgery (especially intracranial, spinal, or ocular).
    • History of allergy or hypersensitivity to aspirin or NSAIDs (urticaria, angioedema, asthma).
    • Gout (can affect uric acid levels).
    • Renal or hepatic impairment.
    • Current medications (especially anticoagulants, other NSAIDs, SSRIs, corticosteroids).
    • Alcohol consumption.
    • Pregnancy status.
  • Adverse Effects: Epigastric pain, melena, hematemesis, bruising, tinnitus, hearing changes, dizziness, shortness of breath, rash.
  • Pediatric use: Recent viral illness (e.g., influenza, varicella) in children/adolescents.
• Red Flags:
  • Active bleeding (hematemesis, melena, hematochezia).
  • Acute severe allergic reaction (anaphylaxis, angioedema).
  • Acute neurological deficit (suggestive of stroke, may be hemorrhagic).
  • Severe acute abdominal pain.
  • Signs of Reye's syndrome in children (vomiting, lethargy, behavioral changes after viral illness).

Laboratory Tests

• First-Line (for monitoring adverse effects/toxicity):
  • Complete Blood Count (CBC): To check for anemia (Hb, Hct) from chronic blood loss; platelet count for baseline.
  • Renal Function Tests (Creatinine, BUN): To assess renal function, as aspirin can impair it, especially at higher doses or in vulnerable patients.
  • Liver Function Tests (ALT, AST, Bilirubin): To assess for hepatic injury (rare, but can occur, especially in toxicity).
  • Coagulation Panel (PT/INR, PTT): To assess baseline clotting status, especially if bleeding is suspected or before invasive procedures. Aspirin prolongs bleeding time, which is not measured by these tests.
  • Salicylate Level: Crucial for suspected aspirin toxicity.
    • Therapeutic anti-inflammatory range: 10-30 mg/dL (100-300 mcg/mL or 0.7-2.2 mmol/L).
    • Mild toxicity (salicylism): >30 mg/dL (300 mcg/mL or 2.2 mmol/L).
    • Moderate to severe toxicity: >50 mg/dL (500 mcg/mL or 3.6 mmol/L).
    • Potentially lethal: >80-100 mg/dL (800-1000 mcg/mL or 5.8-7.2 mmol/L).
• Confirmatory (for complications/toxicity):
  • Arterial Blood Gas (ABG): For aspirin toxicity, often shows respiratory alkalosis initially, progressing to metabolic acidosis.
  • Electrolytes: To check for acid-base disturbances, fluid imbalance in toxicity.
  • Urine pH: Can be used to guide management of aspirin toxicity (alkalinization).
  • Fecal Occult Blood Test (FOBT)/Fecal Immunochemical Test (FIT): For chronic occult GI bleeding.
• Monitoring:
  • Periodic CBC: For patients on long-term aspirin, especially if risk factors for GI bleeding are present.
  • Renal function: Periodically, especially in elderly or those with pre-existing renal impairment.

Imaging

• Recommended (for complications):
  • Upper Endoscopy (EGD): If significant GI bleeding or persistent dyspepsia is suspected, to identify ulcers, erosions, or other sources of bleeding.
  • CT scan of the head: In cases of suspected stroke (to differentiate ischemic from hemorrhagic) or traumatic head injury in patients on aspirin.
• Advanced (for complications):
  • CT Angiography (CTA) or Magnetic Resonance Angiography (MRA): For assessment of vascular pathology in stroke workup.
  • Capsule Endoscopy/Push Enteroscopy: For obscure GI bleeding not identified by EGD/colonoscopy.

Management

Acute Management (for acute indications or toxicity)

• Immediate (for ACS/Ischemic Stroke):
  • Acute Coronary Syndromes (ACS): Administer 162-325 mg (non-enteric coated) aspirin, chewed, immediately upon suspicion of MI, unless contraindicated.
  • Acute Ischemic Stroke: Administer 160-325 mg aspirin orally within 24-48 hours of stroke onset, after excluding hemorrhagic stroke by imaging. Avoid within 24 hours of IV thrombolysis.
• Stabilization (for severe adverse effects):
  • Acute GI Bleeding:
    • Discontinue aspirin.
    • IV fluids for hemodynamic stability.
    • PPI (e.g., pantoprazole 40-80 mg IV bolus, then 8 mg/hr infusion).
    • Endoscopic evaluation and hemostasis.
    • Blood transfusion if significant anemia/hemodynamic instability.
  • Aspirin Toxicity (Salicylate Poisoning):
    • General supportive care: ABCs (Airway, Breathing, Circulation). Correct fluid and electrolyte imbalances.
    • Gastric decontamination: Activated charcoal (1 g/kg, up to 50 g) if within 1-2 hours of ingestion or for extended-release formulations.
    • Alkaline diuresis: IV sodium bicarbonate to maintain urine pH 7.5-8.5. This increases salicylate excretion. Typically, 1-2 ampules (50-100 mEq) in 1 L D5W at 1.5-2 times maintenance fluid rate. Monitor serum potassium and calcium.
    • Hemodialysis: For severe toxicity (salicylate level >90-100 mg/dL), altered mental status, renal failure, persistent acidosis, pulmonary edema, or refractory hypotension.
• Emergency:
  • Anaphylaxis/Severe Hypersensitivity: Epinephrine, antihistamines, corticosteroids.
  • Hemorrhagic Stroke: Immediate neurosurgical consultation, reversal of antiplatelet effect if possible (platelet transfusion in severe cases, though evidence is limited for aspirin reversal alone).

Chronic Management (for prevention)

• Pharmacological:
  • Secondary Prevention of ASCVD:
    • Dosage: 75-162 mg once daily (most commonly 81 mg or 100 mg). 81 mg is preferred in the US, 75 mg or 100 mg common elsewhere.
    • Rationale: Reduces risk of recurrent MI, stroke, and cardiovascular death by preventing thrombus formation on ruptured plaques.
    • Duration: Indefinite for most patients with established ASCVD, unless bleeding risk outweighs benefit.
  • Primary Prevention of ASCVD:
    • Dosage: 75-100 mg once daily (e.g., 81 mg).
    • Rationale: Reduces first cardiovascular event. However, this must be balanced against bleeding risk.
    • Current Guidelines:
      • USPSTF (2022):
        • Age 40-59 years: Individualized decision based on ASCVD risk and bleeding risk. Net benefit is small.
        • Age ≥60 years: Not recommended for primary prevention due to increased risk of bleeding without a net benefit.
      • ACC/AHA (2019):
        • Low-dose aspirin (75-100 mg) may be considered for primary prevention in select high-risk adults (age 40-70 years) who are not at increased bleeding risk.
        • Aspirin should not be administered routinely for primary prevention in adults >70 years.
        • Aspirin should not be administered for primary prevention in adults at increased bleeding risk.
  • Preeclampsia Prevention:
    • Dosage: Low-dose aspirin (81 mg daily).
    • Initiation: Ideally started between 12-16 weeks gestation, continued until delivery.
    • Indications (ACOG/USPSTF): For women at high risk of preeclampsia (e.g., history of preeclampsia, multifetal gestation, chronic hypertension, pre-gestational diabetes, renal disease, autoimmune disease). May also be considered for those with multiple moderate risk factors.
  • Colorectal Cancer Prevention:
    • Dosage: Low-dose aspirin (81 mg/day) for 5-10 years.
    • Rationale: Long-term use may reduce the incidence and mortality of colorectal cancer, possibly through COX-2 inhibition and other mechanisms.
    • Guidelines: USPSTF (2016) recommends low-dose aspirin for primary prevention of CRC and CVD in adults aged 50-59 years with a ≥10% 10-year ASCVD risk and low bleeding risk, with a life expectancy of at least 10 years. Decision is individualized for 60-69 years. Not recommended for ≥70 years.
• Non-pharmacological:
  • Risk factor modification: Crucial for primary and secondary prevention of ASCVD (e.g., smoking cessation, blood pressure control, lipid management, diabetes control, healthy diet, regular exercise).
  • GI protection: Avoid NSAIDs, excessive alcohol.
• Monitoring:
  • Annual review: Reassess ASCVD risk, bleeding risk, and appropriateness of continued aspirin therapy.
  • Symptoms of bleeding: Advise patients to report any signs of GI bleeding, unusual bruising, or persistent nosebleeds.
  • Blood pressure: Regularly monitor, especially in primary prevention, as hypertension is a major risk factor for both ASCVD and hemorrhagic stroke.

Treatment Algorithms

• First-Line (Indications):
  • ACS: Aspirin 162-325 mg chewed immediately. Often continued with P2Y12 inhibitor (e.g., clopidogrel, ticagrelor, prasugrel) as Dual Antiplatelet Therapy (DAPT).
  • Ischemic Stroke/TIA: Aspirin 160-325 mg within 24-48 hours. For minor stroke/high-risk TIA, DAPT (aspirin + clopidogrel) may be used for 21-30 days.
  • Secondary ASCVD Prevention: Aspirin 81 mg daily indefinitely.
• Second-Line:
  • Not applicable as a "second-line" for aspirin itself, but for patients intolerant to aspirin or with contraindications, alternative antiplatelet agents (e.g., clopidogrel) or anticoagulants may be considered depending on the indication.
• Refractory Cases:
  • Aspirin Resistance: A controversial concept; refers to patients who experience thrombotic events despite aspirin therapy. Clinical relevance and definitive testing are debated. Often, dose optimization or addition of another antiplatelet agent (DAPT) is considered rather than increasing aspirin dose significantly.
  • Recurrent GI bleeding on aspirin: Consider higher dose PPI, H. pylori eradication, or discontinuation of aspirin if risk outweighs benefit. If aspirin is essential, consider alternative antiplatelet.

Complications

• Common:
  • Gastrointestinal: Dyspepsia, nausea, vomiting, abdominal pain, heartburn, erosive gastritis, peptic ulcers.
  • Bleeding: Increased bleeding time, easy bruising, epistaxis, gingival bleeding, menorrhagia, GI bleeding (occult or overt).
• Serious:
  • Major Hemorrhage: Upper GI bleeding (hematemesis, melena), hemorrhagic stroke, intracranial hemorrhage, retroperitoneal hemorrhage. Risk increases with age, history of ulcers/bleeding, concomitant anticoagulants/NSAIDs, H. pylori infection, high alcohol intake.
  • Aspirin-Exacerbated Respiratory Disease (AERD): Severe bronchospasm, rhinorrhea, nasal polyps in susceptible individuals (asthma, chronic rhinosinusitis).
  • Hypersensitivity/Allergy: Urticaria, angioedema, anaphylaxis (rare).
  • Reye's Syndrome: Acute encephalopathy and fatty liver degeneration in children and adolescents recovering from viral infections (especially influenza and varicella). Potentially fatal.
  • Renal Impairment: Papillary necrosis, acute kidney injury, particularly in patients with pre-existing renal disease, heart failure, or concurrent nephrotoxic drugs.
  • Tinnitus/Ototoxicity: Dose-dependent, often reversible upon discontinuation. A sign of salicylism.
  • Salicylate Poisoning (Overdose): Metabolic acidosis, respiratory alkalosis, hyperthermia, dehydration, seizures, coma, multiorgan failure.
• Long-term:
  • Anemia: Chronic iron deficiency anemia due to occult GI blood loss.
  • Chronic kidney disease progression: In susceptible individuals.

Prognosis

• Factors:
  • Bleeding risk: Major factor influencing net benefit, especially in primary prevention.
  • Cardiovascular risk burden: Higher risk often means higher absolute benefit from aspirin.
  • Patient adherence: Consistent daily dosing is key for efficacy.
  • Concomitant medications: Interactions with other drugs can affect efficacy or increase risks.
  • Age: Older patients have higher bleeding risk, potentially reducing net benefit for primary prevention.
• Survival:
  • Secondary prevention: Aspirin significantly reduces recurrent MI, stroke, and cardiovascular death, improving long-term survival in patients with established ASCVD.
  • Primary prevention: Net effect on all-cause mortality is often neutral or slightly positive due to balancing cardiovascular benefit with bleeding harm.
• Quality of Life:
  • For secondary prevention, reduced recurrent events contribute to improved quality of life.
  • Adverse effects, particularly chronic GI symptoms or bleeding, can negatively impact quality of life.

Prevention

• Primary Prevention (of thrombotic events):
  • Indication: As discussed under Chronic Management. For selected individuals aged 40-59 years with ≥10% 10-year ASCVD risk and low bleeding risk. Generally not recommended for ≥60 years.
  • Dosage: Low-dose aspirin (81 mg daily).
• Secondary Prevention (of thrombotic events and complications):
  • Indication: Patients with established ASCVD (history of MI, stroke, TIA, PAD, stable angina).
  • Dosage: Low-dose aspirin (81 mg daily) indefinitely.
  • Prevention of Preeclampsia: Low-dose aspirin in high-risk pregnancies.
  • Prevention of Colorectal Cancer: Long-term low-dose aspirin in selected high-risk individuals.
• Tertiary Prevention (of complications from aspirin use):
  • GI protection: Co-prescription of a PPI (e.g., omeprazole 20-40 mg daily) or H2 blocker for patients at high risk of GI bleeding (e.g., history of ulcer, concomitant anticoagulants/corticosteroids, elderly).
  • Patient education: Inform patients about signs of bleeding and when to seek medical attention.
  • Regular risk reassessment: Periodically re-evaluate the risk-benefit profile for long-term aspirin use.

Special Populations

• Pediatric:
  • Contraindication: Generally contraindicated in children and adolescents (<18 years) for viral illnesses (e.g., influenza, varicella) due to the risk of Reye's Syndrome.
  • Exceptions: Kawasaki disease, juvenile idiopathic arthritis, specific post-cardiac surgery indications (under specialist supervision).
• Geriatric:
  • Increased Bleeding Risk: Higher risk of major bleeding, especially GI and intracranial hemorrhage, due to age-related factors (e.g., frailty, polypharmacy, increased comorbidities).
  • Renal Impairment: More susceptible to aspirin-induced renal dysfunction.
  • Primary prevention: Generally not recommended for primary prevention of ASCVD in adults ≥70 years due to net harm from bleeding.
  • Secondary prevention: Benefits usually outweigh risks in patients with established ASCVD, but careful monitoring is required.
• Pregnancy:
  • First Trimester: Generally avoided due to theoretical risk of teratogenicity, though evidence is not conclusive for low doses. High doses associated with omphalocele and gastroschisis.
  • Second Trimester: Low-dose aspirin (81 mg) is routinely recommended for preeclampsia prevention in high-risk women (initiated 12-16 weeks gestation).
  • Third Trimester: High doses can cause premature closure of the ductus arteriosus, pulmonary hypertension, and antiplatelet effects in the neonate. Generally avoided or used cautiously at low doses, especially after 30-32 weeks gestation, unless compelling obstetric indication.
  • Breastfeeding: Low-dose aspirin is generally considered safe as very little is secreted in breast milk.
• Comorbidities:
  • Chronic Kidney Disease (CKD): Use with caution, monitor renal function. Avoid high doses. Increased risk of fluid retention.
  • Liver Disease: Increased bleeding risk due to impaired clotting factor synthesis. Use with caution.
  • Asthma/AERD: Absolute contraindication if history of aspirin-exacerbated respiratory disease (AERD).
  • Peptic Ulcer Disease/GI Bleeding History: High risk of recurrence. Co-prescription of PPI is strongly recommended.
  • Gout: Aspirin can elevate serum uric acid at low doses and decrease it at high doses. May interfere with uricosuric agents. Generally avoided in active gout attacks.
  • Diabetes Mellitus: Patients with diabetes are at high risk for ASCVD. Primary prevention decisions should follow current guidelines, weighing individual ASCVD and bleeding risks.

Clinical Pearls

• Diagnostic:
  • "Silent" bleeds: Always consider chronic GI blood loss leading to iron deficiency anemia in patients on long-term aspirin, even without overt GI symptoms. Check ferritin and CBC.
  • Tinnitus as a red flag: Tinnitus can be an early sign of aspirin toxicity (salicylism); inquire about other symptoms like dizziness or nausea.
• Treatment:
  • Chew for faster absorption: In acute coronary syndromes, chewing non-enteric coated aspirin (162-325 mg) allows for faster absorption and antiplatelet effect.
  • Enteric coating: While designed to reduce GI upset, enteric-coated aspirin may have delayed or erratic absorption and does not eliminate the risk of GI bleeding, as systemic antiplatelet effects still occur. It is generally not preferred for acute indications.
  • PPI co-therapy: Strongly consider a PPI for patients on long-term aspirin with increased GI bleeding risk factors (e.g., history of ulcer, age >60, concomitant NSAIDs/corticosteroids/anticoagulants).
  • Timing of dose: Some suggest taking aspirin with food to minimize GI upset. For primary prevention, consistent daily timing is more important than specific meal times.
• Pitfalls:
  • Underestimation of bleeding risk: Overlooking or downplaying a patient's individual bleeding risk can lead to serious adverse events, especially in primary prevention.
  • Ignoring contraindications: Administering aspirin in the presence of absolute contraindications (e.g., active bleeding, severe allergy, Reye's syndrome risk in children) is a major pitfall.
  • Automatic "aspirin for everyone": The landscape for primary prevention has changed; it is no longer a universal recommendation. Individualized risk assessment is critical.
  • Discontinuing aspirin pre-procedure without indication: For minor procedures with low bleeding risk (e.g., dental procedures, dermatologic biopsies), aspirin often does not need to be stopped, especially in patients at high thrombotic risk. Discuss with proceduralist. For high-risk procedures, discuss with cardiologist/prescribing physician.

Recent Updates

• Guidelines (Primary Prevention):
  • USPSTF (2022): Significantly narrowed the recommendation for aspirin in primary prevention. Now recommends against initiating aspirin for primary prevention of ASCVD in adults ≥60 years due to increased bleeding risk. For ages 40-59 years, the decision is individualized. This is a major shift from previous broader recommendations.
  • ACC/AHA (2019): Aligned with the shift, emphasizing individualized decision-making for primary prevention, particularly in adults aged 40-70 who are not at increased bleeding risk, and recommending against routine use in older adults (>70 years) or those with increased bleeding risk.
• Evidence:
  • ARRIVE, ASCEND, ASPREE Trials (2018): These large randomized controlled trials further clarified the risk-benefit balance for primary prevention.
    • ARRIVE: Low-risk individuals showed no benefit in reducing CVD events but increased bleeding risk.
    • ASCEND: In diabetics, modest reduction in serious vascular events but increased major bleeding.
    • ASPREE: In healthy older adults (>70 years), no significant benefit on CVD or all-cause mortality but increased major hemorrhage.
  • These trials collectively strengthened the evidence against routine aspirin use for primary prevention in low-to-moderate risk individuals and older adults.
• Controversies:
  • Aspirin resistance: Still a debated concept, with no consensus on clinical utility of testing or specific management strategies.
  • Optimal duration of DAPT: While not purely an aspirin controversy, the ideal duration of dual antiplatelet therapy (aspirin + P2Y12 inhibitor) after ACS/PCI continues to be refined based on balancing ischemic and bleeding risks.
  • Role in cancer prevention: While evidence suggests a role in colorectal cancer prevention, the specific dose, duration, and target population are still areas of ongoing research and not yet universally integrated into screening guidelines as a primary prevention strategy outside specific subgroups.

Key References

• Guidelines:
  • USPSTF (U.S. Preventive Services Task Force) Recommendation Statement on Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer (2022).
  • 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease.
  • ACCF/AHA/SCAI/SCOT/SIR/STS/TVT 2017 Expert Consensus Decision Pathway for Periprocedural Management of Antithrombotic Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism.
  • ACOG (American College of Obstetricians and Gynecologists) Practice Bulletin No. 222: Gestational Hypertension and Preeclampsia (2020).
• Studies:
  • ASPREE (ASPirin in Reducing Events in the Elderly) Study (2018): N Engl J Med. 2018;379(16):1503-1513.
  • ASCEND (A Study of Cardiovascular Events in Diabetes) Trial (2018): N Engl J Med. 2018;379(16):1529-1539.
  • ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) Trial (2018): Lancet. 2018;392(10152):1036-1046.
  • Antiplatelet Trialists' Collaboration (1994, 2002): Meta-analyses demonstrating the benefits of antiplatelet therapy in cardiovascular disease.
• Reviews:
  • UpToDate topic reviews on Aspirin for primary and secondary prevention, management of aspirin toxicity, and antiplatelet therapy.
  • American Heart Association/American College of Cardiology scientific statements and consensus documents on antiplatelet therapy.

---

Disclaimer: This information is intended for educational purposes for healthcare professionals and should not be used as a substitute for professional medical advice. Always consult current guidelines and apply clinical judgment.